DCTH

Delcath Systems, Inc.

2.88 USD
-0.10 (-3.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Delcath Systems, Inc. stock is down -2.37% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56.52% of the previous 22 December’s closed higher than November.

About Delcath Systems, Inc.

Delcath Systems, Inc. focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver.